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Abstract
N‐methyl‐D‐aspartate	(NMDA)	receptors	are	glutamate	receptors	with	key	roles	in	
synaptic	plasticity,	due	in	part	to	their	Mg2+	mediated	voltage‐dependence.	A	large	
number	 of	 genetic	 variants	 affecting	 NMDA	 receptor	 subunits	 have	 been	 found	
in	 people	 with	 a	 range	 of	 neurodevelopmental	 disorders,	 including	 GluN2AN615K 
(GRIN2AC1845A)	 in	 two	 unrelated	 individuals	with	 severe	 epileptic	 encephalopathy.	
This missense variant substitutes a lysine in place of an asparagine known to be im‐
portant for blockade by Mg2+ and other small molecule channel blockers. We there‐
fore	measured	 the	 impact	of	GluN2AN615K	on	a	 range	of	NMDA	receptor	channel	
blockers using two‐electrode voltage clamp recordings made in Xenopus oocytes. 
We	 found	 that	 GluN2AN615K resulted in block by Mg2+	 1	 mmol/L	 being	 greatly	  
reduced	(89%	vs	8%),	block	by	memantine	10	μmol/L	(76%	vs	27%)	and	amantadine	
100 μmol/L	(45%	vs	17%)	being	substantially	reduced,	block	by	ketamine	10	μmol/L	
being	modestly	reduced	 (79%	vs	73%)	and	block	by	dextromethorphan	10	μmol/L	
being	enhanced	(45%	vs	55%).	Coapplying	Mg2+ with memantine or amantadine did 
not	reduce	the	GluN2AN615K	block	seen	with	either	small	molecule.	In	addition,	we	
measured	single–channel	conductance	of	GluN2AN615K–containing	NMDA	receptors	
in outside‐out patches pulled from Xenopus	 oocytes,	 finding	 a	4‐fold	 reduction	 in	
conductance	(58	vs	15	pS).	In	conclusion,	the	GluN2AN615K variant is associated with 
substantial changes to important physiological and pharmacological properties of the 
NMDA	 receptor.	Our	 findings	 are	 consistent	with	GluN2AN615K having a disease–
causing	role,	and	inform	potential	therapeutic	strategies.
K E Y W O R D S
blocker,	channel,	epilepsy,	human,	magnesium,	mutation,	NMDA,	receptor,	variant
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1  | INTRODUC TION
N‐methyl‐D‐aspartate receptors are calcium‐permeable ligand‐
gated glutamate receptors which unusually are blocked at rest by 
Mg2+ ions and thus also require postsynaptic depolarization in order 
to allow current flow.1,2 This dual requirement for activation affords 
them	crucial	roles	in	synapse	formation,	plasticity	and	maintenance.3 
Consistent	with	these	important	roles,	NMDA	receptor	dysfunction	
has been linked to a range of neurodevelopmental and neurodegen‐
erative disorders3 with a range of small molecules developed which 
influence	NMDA	receptor	function	and	which	are	 licensed	for	use	
in humans. The development of personalized medicine may allow 
these	small	molecules	to	be	used	in	new	situations,	as	clarifying	the	
biological consequences of newly identified genetic variants allows 
repurposing	of	existing	medications	(for	example	4).
NMDA	receptors	are	heterotetramers	containing	two	obligatory	
GluN1	subunits	and	two	others,	of	which	GluN2A	and	GluN2B	are	
the commonest in the postnatal mammalian forebrain.5 Where two 
types	of	subunits	are	present	the	receptor	is	termed	a	diheteromer,	
where	three	types	are	present,	a	triheteromer.	Over	the	last	decade	
a large and increasing number of variants in the genes encoding 
NMDA	receptor	subunits	have	been	identified	in	people	with	neuro‐
developmental	disorders	including	intellectual	disability,	schizophre‐
nia,	autism	and	epilepsy.6 Variants in GRIN2A are most likely to be 
associated	with	epilepsy	aphasia	syndromes,	with	the	location	and	
nature	of	the	variant	 (loss	of	function	vs	missense)	 influencing	the	
severity of the phenotype seen.7	The	missense	variant	GluN2AN615K 
is associated with a severe phenotype of early onset epileptic en‐
cephalopathy in two unrelated individuals.8,9 It substitutes a lysine 
(positively	charged)	for	an	asparagine	(neutral)	 in	the	M2	region	of	
the	NMDA	 receptor	 pore,	 in	 one	 of	 the	 narrowest	 regions	 of	 the	
pore.10 The residue affected is the most important determinant of 
Mg2+	block	in	GluN2A	subunits:	the	“N	+	1”	site	(an	asparagine	that	
neighbors	the	QRN	site	asparagine	in	GluN2A).11
Previous	 work	 has	 shown	 that	 the	 GluN2AN615K variant has 
profound	effect	on	NMDA	 receptor	properties:	 it	 reduces	block	by	
Mg2+4,9,12	and	influences	block	by	other	channel	blockers,4 it reduces 
calcium permeability 9 and it reduces single–channel conductance.12 
Importantly,	 the	 variant	 influences	 receptor	 properties	 even	 when	
only one copy is present in a receptor.12 Some of these effects could 
be	viewed	as	 “gain	of	 function”,	 some	 “loss	of	 function”.	Seeking	 to	
reverse	the	“gain	of	function”	component	could	be	aided	by	the	use	of	
channel	blockers,	as	has	been	trialed	successfully	by	the	use	of	meman‐
tine in a child carrying a different GRIN2A variant.4	To	do	this,	detailed	
knowledge of the effect of channel blockers on receptors containing 
the	GluN2AN615K	variant	in	physiological	contexts	is	required.
In	 this	study	we	therefore	sought	 to	 replicate	and	extend	pre‐
vious work demonstrating a reduced potency of memantine and 
amantadine,4 by investigating the degree of inhibition by these 
blockers in the presence and absence of physiological concentra‐
tions of Mg2+.	We	examined	the	previously	uninvestigated	blocker	
ketamine.	In	addition,	we	replicated	our	previous	finding	of	a	reduc‐
tion in single‐channel conductance12 in a different system using a 
different method of measurement. Our findings show that blocking 
GluN2AN615K	 –containing	 NMDA	 receptors	 using	 memantine	 or	
amantadine remains possible in the presence of Mg2+,	but	that	dex‐
tromethorphan is a more promising therapeutic candidate due to its 
increased inhibition in the presence of the variant.
2  | METHODS
2.1 | Test system used
Xenopus laevis	oocytes	were	used	in	all	experiments	reported	here.	
Experiments	conducted	during	the	course	of	this	study	received	ap‐
proval	 from	 the	 University	 of	 Edinburgh's	 Animal	Welfare	 Ethical	
Review	 Board.	 Stage	 V‐VI	 oocytes	 were	 obtained	 from	 the	 UK	
Xenopus	centre	(Portsmouth,UK)	and	from	Diaclean	(CastropRauxel,	
Germany).	Maintenance	and	culling	of	animals	was	performed	by	the	
oocyte	providers.	Approximately	200	oocytes	were	gathered	from	
each of the eight Xenopus laevis used.
2.2 | cRNA synthesis and expression in oocytes
The	cDNA	 for	wild	 type	human	NMDA	subunit	GluN1‐1a	 (hereaf‐
ter	 GluN1)	 and	 GluN2A	 (GenBank	 accession	 codes:	 NP_015566,	
NP_000824)13	 were	 gifts	 from	 Dr	 Hongjie	 Yuan	 (University	 of	
Emory).	 All	 cDNAs	were	 in	 pCI‐neo.	 Site‐directed	mutagenesis	 to	
generate	 GluN2AN615K was performed as described previously12 
using	 a	 mutagenizing	 polymerase	 chain	 reaction,	 recircularization	
and transformation. The mutation was verified using Sanger se‐
quencing through the mutated region.
cRNA	synthesis	and	expression	was	performed	as	described	previ‐
ously.14	cRNA	for	wild	type	and	mutant	subunits	was	synthesized	from	
linearized	plasmid	DNA	as	runoff	transcripts	using	the	T7	polymerase	
mMessage	mMachine	RNA	synthesis	kit	(Life	Technologies	Ltd,	Paisley,	
UK).	Each	oocyte	was	injected	with	3.7‐9	ng	of	cRNA,	comprising	a	1:1	
molar	ratio	of	GluN1	and	GluN2A	diluted	in	RNAse	free	water.
Prior	to	 injection	oocytes	were	collagenased	(200	units/mL	for	
60	min),	then	manually	defolliculated.	After	injection	oocytes	were	
placed	 in	modified	 Barth's	 solution	with	 composition	 (in	mmol/L):	 
88	NaCl,	1	KCl,	2.4	NaHCO3,	0.82	MgCl2,	0.44	CaCl2,	0.33	Ca(NO3)2,	
15	Tris‐HCl,	adjusted	to	pH	7.35	with	NaOH.	This	solution	was	sup‐
plemented	 with	 50	 IU/mL	 penicillin,	 50	 mg/mL	 streptomycin	 and	
50	mg/mL	tetracycline.	Oocytes	were	 then	placed	 in	an	 incubator	
(16‐21°C)	 for	 24‐48	 hours	 to	 encourage	 receptor	 expression	 and	
subsequently	stored	at	4°C.
Recordings	were	made	48‐96	hours	post	injection.
2.3 | Measurements made
2.3.1 | Two‐electrode voltage‐clamp recordings
Two‐electrode voltage‐clamp recordings were performed as de‐
scribed previously.14 Recordings were made at room temperature 
(18‐21°C)	from	oocytes	that	were	placed	in	a	solution	that	contained	
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(in	mmol/L):	 115	NaCl,	 2.5	 KCl,	 10	HEPES,	 1.8	 BaCl2,	 0.01	 EDTA;	
pH	 7.35	 with	 NaOH.	 Recordings	 were	 made	 using	 a	 GeneClamp	
500B	 amplifier	 (Molecular	 Devices,	 Union	 City,	 CA).	 Current	 and	
voltage electrodes were made from thin‐walled borosilicate glass 
(GC150TF‐7.5,	Harvard	Apparatus,	Kent,	UK)	 using	 a	 PP‐830	 elec‐
trode	puller	(Narashige	Instruments,	Japan).	Filling	with	3	M	KCl	gave	
resistances	of	between	0.2	and	1.5	mol/L.	Bath	application	of	solu‐
tions	was	performed	manually.	Data	were	filtered	at	10	Hz	and	digi‐
tized	at	100	Hz	via	a	1401	plus	analogue‐digital	interface	(Cambridge	
Electronic	 Design,	 Cambridge,	 UK)	 using	 WinEDR	 software	
(Strathclyde	 Electrophysiology	 Software,	 Strathclyde	 University,	
UK).	Recordings	were	rejected	if	the	holding	current	at	–60	mV	was	
greater	than	150	nA	or	if	the	holding	current	drifted	by	more	than	5%	
of	the	agonist	response	across	the	course	of	the	experiment.
2.3.2 | Single‐channel voltage‐clamp recordings
Single‐channel voltage‐clamp recordings were made as described 
previously.14	Recordings	were	made	at	room	temperature	(18‐21°C)	
from outside‐out patches pulled from oocytes that were placed in a 
solution	that	contained	(in	mmol/L):	125	NaCl,	3	KCl,	1.25	NaH2PO4,	
20	HEPES,	0.85	CaCl2,	0.01	EDTA;	pH	7.35	with	NaOH.	Recording	
durations	varied	from	30	seconds	to	5	minutes.	Prior	 to	recording	
vitelline membranes were removed from oocytes placed in a hyper‐
tonic	solution	that	contained	(in	mmol/L):	200	sodium	methyl	sulfate,	
20	KCl,	 10	HEPES,	1	MgCl2,	 pH	7.4	with	NaOH.	Recordings	were	
made	using	an	AxoPatch	1D	amplifier	(Molecular	Devices).	Patch	pi‐
pettes	were	made	using	thick	walled	borosilicate	glass	(GC150F‐7.5,	
Harvard	Apparatus)	using	a	P‐87	electrode	puller	(Sutter	Instrument,	
Novato,	CA)	and	their	tips	fire	polished	to	give	resistances	of	7	to	
12 MΩ	 when	 filled	 with	 internal	 solution	 containing	 (in	 mmol/L):	
2.5	NaCl,	141	K‐gluconate,	10	HEPES,	11	EGTA;	pH	7.4	with	KOH.	
Electrode	tips	were	coated	in	silicone	elastomer	(“Sylgard	184”,	Dow	
Corning,	Wiesbaden,	Germany)	 to	reduce	capacitance.	Application	
of	solutions	was	controlled	manually.	Data	were	prefiltered	at	2	kHz	
(–3	dB,	8th	order	Bessel	 filter)	and	digitized	at	20	kHz	via	a	Micro	
1401	 analogue‐digital	 interface	 (Cambridge	 Electronic	 Design)	
using	WinEDR	 software	 (Strathclyde	 Electrophysiology	 Software).	
Patches	were	voltage‐clamped	at	–60	or	–100	mV.
2.4 | Data analysis and statistical procedures
WinEDR	 v3.3.7	 (http://spider.science.strath.ac.uk/sipbs/software_
ses.htm)	 was	 used	 to	 analyze	 all	 data.	 For	 two‐electrode	 voltage	
clamp	recordings,	steady	state	averages	were	taken	for	baseline,	re‐
sponse	to	glutamate,	and	response	to	channel	blockers,	and	percent‐
age	inhibition	of	the	agonist	response	calculated.	For	single‐channel	
recordings,	 traces	 were	 idealized	 (using	 a	 transition	 threshold	 of	
50%	of	the	unitary	conductance	level	and	a	100	μs open and shut 
resolution)	and	amplitude	histograms	plotted.	Gaussian	curves	were	
fitted	to	the	currents	seen	 in	channel	closed	and	open	states,	and	
the amplitude difference calculated. Conductance was calculated by 
dividing the current amplitude of an open channel by the holding 
potential.	Any	openings	where	more	than	one	channel	was	open	si‐
multaneously were discarded.
Bar	graphs	depict	 individual	cells	 (circles),	means	(columns)	and	
standard	 error	 of	 the	mean	 (error	 bars).	 R	 (v	 3.1.2)	 (R	Core	Team,	
2014)	was	used	to	perform	statistical	tests.	Comparisons	between	
multiple	means	were	performed	using	ANOVA,	with	post	hoc	tests	
performed if the F test was significant for a main effect. Comparisons 
between	two	means	were	performed	using	independent,	two‐tailed,	
Welch t‐tests	(which	do	not	assume	equal	variance	between	groups)	
unless otherwise stated. Correction for multiple comparisons were 
made	using	the	Bonferroni	method.	The	significance	level	used	was	
P	<	0.05.	In	figures,	*	indicates	P	<	0.05,	**	indicates	P	<	0.01	and	***	
indicates P < 0.001.
2.5 | Compliance with design and statistical analysis 
requirements
Oocytes were randomly allocated for injection with either WT or mu‐
tant	cDNA.	The	experimenter	was	not	blinded	to	construct	as	this	was	
thought	unlikely	to	influence	the	electrophysiological	recordings.	All	
n	refer	to	number	of	oocytes,	not	number	of	traces.	Although	groups	
were	designed	to	have	equal	n	values,	application	of	exclusion	rules	
following	recording	(see	above)	meant	that	groups	ended	up	unequal	
in size. The t‐tests used for comparisons adjust for resulting unequal 
variance. In the case of single‐channel recordings the n numbers re‐
ported are less than 5 but data obtained are highly consistent.
2.6 | Drugs, reagents and other materials
Memantine,	 amantadine,	 ketamine,	 and	 dextromethorphan	 were	
purchased	from	Tocris	Bioscience	(Bristol,	UK).	The	remaining	sub‐
stances	were	purchased	from	Sigma‐Aldrich	(St	Louis,	MO).
3  | RESULTS
3.1 | GluN2AN615K alters the inhibition of a range of 
NMDA receptor channel blockers, including Mg2+
To	assess	the	impact	of	the	GluN2AN615K mutation on inhibition by 
Mg2+	and	small	molecule	channel	blockers,	we	made	two‐electrode	
voltage‐clamp	 recordings	 from	 oocytes	 expressing	 GluN2AWT or 
GluN2AN615K	diheteromeric	NMDA	receptors	exposed	to	glutamate	
(30 μmol/L)	and	glycine	(30	μmol/L)	while	voltage‐clamped	at	–60	mV.	
We	 found	 that	block	by	an	approximately	physiological	 concentra‐
tion of Mg2+	 (1	mmol/L)	was	markedly	reduced	in	oocytes	express‐
ing	 GluN2AN615K	 (Figure	 1A‐D).	We	 also	 found	 that	 the	 maximum	
percentage	 inhibition	 by	 saturating	 concentrations	 of	 memantine,	
amantadine	and	ketamine	was	reduced	by	the	GluN2AN615K variant 
(Figure	1A‐D,	2A‐C).	Coapplying	Mg2+ with memantine or amantadine 
did	not	reduce	their	ability	to	block	GluN2AN615K–containing	NMDA	
receptors	(Figure	2C,D).	In	contrast	to	the	other	channel	blockers,	the	
maximal	inhibition	by	dextromethorphan	was	modestly	increased	by	
the	presence	of	the	GluN2AN615K	variant	(Figure	2D‐F).
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3.2 | GluN2AN615K reduces single–channel 
conductance
In	 view	 of	 the	 profound	 influence	 of	 the	 GluN2AN615K mutation 
on	channel	blockade	we	next	assessed	the	variant's	 impact	on	 ion	
permeation.	In	outside‐out	patches	pulled	from	oocytes	expressing	
GluN2AWT	or	GluN2AN615K	–containing	NMDA	receptors	we	identi‐
fied	a	4‐fold	reduction	in	single–channel	conductance	(Figure	3).
4  | DISCUSSION
4.1 | GluN2AN615K influences degree of blockade by 
NMDA receptor channel blockers
We	found	 that	GluN2AN615K reduced the inhibition caused by the 
small	molecule	channel	blockers	memantine,	amantadine	and	keta‐
mine,	while	increasing	the	inhibition	caused	by	dextromethorphan.	
F I G U R E  1  GluN2AN615K reduces Mg2+,	memantine	and	amantadine	block.	A	and	B,	Representative	two‐electrode	voltage‐clamp	
recordings	made	from	oocytes	expressing	GluN2AWT	or	GluN2AN615K–containing	NMDA	receptors	showing	response	to	glutamate	
(30 μmol/L)	and	inhibition	by	memantine	(10	μmol/L),	Mg2+	(1	mmol/L)	and	the	two	combined,	in	the	continuous	presence	of	glycine	
(30 μmol/L).	Holding	potential	–60	mV.	C,	Summary	data	showing	percentage	inhibition	by	memantine	(10	μmol/L),	Mg2+	(1	mmol/L)	and	
the	two	combined	for	oocytes	transfected	with	either	GluN2AWT	or	GluN2AN615K	–containing	NMDA	receptors,	voltage‐clamped	at	
−60	mV.	A	two‐way	repeated	measures	ANOVA	(blocker	as	within	subjects	factor,	subunit	as	between	subjects	factor)	showed	a	significant	
main effect of channel blocker (F2,39	=	26.1,	P	=	6.4E‐8)	and	of	subunit	(F1,39	=	588.3,	P	<	2E‐16)	with	a	significant	two‐way	interaction	
(F2,39	=	7.3,	P	=	0.002).	Planned	post	‐hoc	Bonferroni	corrected	independent	Welch	t‐tests	showed	that	GluN2A
N615K was associated with 
lower	blockade	by	memantine	(WT:	76	±	1%,	N615K:	27	±	2%,	t10.1	=	17.1,	P	=	4.9E‐8),	by	Mg
2+ (WT:	89	±	1%,	N615K:	8	±	3%,	t7.4	=	23.2,	
P	=	1.8E‐7)	and	by	the	two	combined	(WT:	94	±	1%,	N615K:	29	±	4%,	t6.4	=	15.7,	P	=	1.2E‐5).	Planned	post‐hoc	Bonferroni	corrected	paired	
t‐tests showed that combining memantine and Mg2+	led	to	a	higher	degree	of	block	in	oocytes	expressing	GluN2AWT subunits t8	=	17.5,	
P	=	5.8E‐7)	but	not	in	those	expressing	GluN2AN615K subunits (t6	=	1.4,	P	>	0.2)	(WT:	n	=	9	oocytes,	N615K:	n	=	7	oocytes).	D,	Summary	data	
showing percentage inhibition by amantadine (100 μmol/L),	Mg2+	(1	mmol/L)	and	the	two	combined	for	oocytes	transfected	with	either	
GluN2AWT	or	GluN2AN615K	–containing	NMDA	receptors,	voltage‐clamped	at	–60	mV.	A	two‐way	repeated	measures	ANOVA	(blocker	as	
within	subjects	factor,	subunit	as	between	subjects	factor)	showed	a	significant	main	effect	of	channel	blocker	(F2,39	=	146.5,	P	<	2E‐16)	and	
of subunit (F1,39	=	481.8,	P	<	2E‐16)	with	a	significant	two‐way	interaction	(F2,39	=	20.0,	P	=	1E‐6).	Planned	post‐hoc	Bonferroni	corrected	
independent Welch t‐tests	showed	that	GluN2AN615K	was	associated	with	lower	blockade	by	amantadine	(WT:	45	±	4%,	N615K:	17	±	1%,	
t10.3	=	7.3,	P	=	2.2E‐5),	by	Mg
2+ (WT:	88	±	1%,	N615K:	6	±	1%,	t13.7	=	39.9,	P	=	7.0E‐15)	and	by	the	two	combined	(WT:	91	±	1%,	N615K:	
20	±	4%,	t7.2	=	19.2,	P	=	1.4E‐15).	Planned	post‐hoc	Bonferroni	corrected	paired	t‐tests showed that combining memantine and Mg
2+ led to 
a	higher	degree	of	block	in	oocytes	expressing	GluN2AWT subunits (t8	=	14.5,	P	=	2.5E‐6)	but	not	in	those	expressing	GluN2A
N615K subunits 
(t6	=	1.2,	P	>	0.3)	(WT:	n	=	9	oocytes,	N615K:	n	=	7	oocytes)
2A WT 2A N615K
Memanne ± Mg
2A N615K
2A WT
2+ Amantadine ± Mg2+
2A N615K
2A WT
(A)
(C) (D)
(B)
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This is consistent with previous work4 and with work identifying 
overlap between residues important for Mg2+ block and residues im‐
portant for binding of memantine 10,15 and ketamine.16	Amantadine	
is structurally very similar to memantine so is likely to interact with 
similar	 residues.	 In	contrast,	dextromethorphan's	primary	metabo‐
lite	 dextrorphan	 interacts	 with	 residues	 in	 the	 more	 extracellular	
portion of the vestibule.17 Our data suggest that this interaction is 
nonetheless	 altered	by	 the	GluN2AN615K variant deeper in the re‐
ceptor	pore.	This	may	be	of	potential	therapeutic	relevance	as	dex‐
tromethorphan is already licensed for use in humans (it is a common 
ingredient	 in	 cough	 medicines).	 However,	 the	 enhanced	 block	 of	
GluN2AN615K	 –containing	 receptors	 by	 dextromethorphan	 would	
only be of benefit if the primary problem caused by the variant was 
receptor	hyperfunction,	rather	than	hypofunction.	Our	findings	and	
previous work show that the variant is associated with alterations 
in receptor properties which could potentially lead to either out‐
come,	so	this	would	need	to	be	investigated	cautiously.	Further,	the	
increase	 in	block	 in	GluN2AN615K	–containing	receptors	 is	modest,	
meaning	 that	 the	 effects	 of	 any	 given	 dose	 of	 dextromethorphan	
on wild type receptors would also need to be considered and could 
potentially be harmful.
We also found that coapplying Mg2+ with the channel blockers me‐
mantine	and	amantadine	had	no	effect	on	the	maximal	GluN2AN615K 
block observed with the small molecules. This suggests that these 
drugs	could	still	be	expected	to	cause	some	block	of	GluN2AN615K –
containing	NMDA	receptors	in	vivo,	but	that	they	would	cause	more	
block at wild type receptors. This would likely limit their therapeutic 
utility,	unless	compensatory	processes	in	some	way	caused	wild	type	
NMDA	receptor	overactivation.	Our	finding	that	wild	type	subunits	
show higher block when memantine or amantadine are coapplied with 
Mg2+ than when either are applied alone is consistent with work done 
in the same system with the same concentrations of blocker used.18
4.2 | GluN2AN615K reduces single–channel 
conductance
We	 found	 that	 GluN2AN615K	 –containing	 NMDA	 receptors	
showed a 4‐fold reduction in single–channel conductance. The 
F I G U R E  2  GluN2AN615K	reduces	ketamine	block	but	increases	dextromethorphan	block.	A	and	B,	Representative	two‐electrode	voltage‐
clamp	recordings	made	from	oocytes	expressing	GluN2AWT	or	GluN2AN615K–containing	NMDA	receptors	showing	response	to	glutamate	
(30 μmol/L)	and	inhibition	by	ketamine	(10	μmol/L)	in	the	continuous	presence	of	glycine	(30	μmol/L).	Holding	potential	–60	mV.	C,	Summary	
data showing percentage inhibition by ketamine (10 μmol/L)	for	oocytes	transfected	with	either	GluN2AWT	or	GluN2AN615K –containing 
NMDA	receptors,	voltage‐clamped	at	–60	mV.	An	independent	Welch	t‐test	showed	that	GluN2AN615K was associated with a reduction in 
block	(WT:	79	±	2	(n	=	11	oocytes),	N615K:	73	±	1	(n	=	6	oocytes),	t14.9	=	2.6,	P	=	0.019).	D	and	E,	Representative	two‐electrode	voltage‐
clamp	recordings	made	from	oocytes	transfected	with	GluN2AWT	or	GluN2AN615K–containing	NMDA	receptors	showing	response	to	
glutamate (30 μmol/L)	and	inhibition	by	dextromethorphan	(10	μmol/L)	in	the	continuous	presence	of	glycine	(30	μmol/L).	Holding	potential	
–60	mV.	F,	Summary	data	showing	percentage	inhibition	by	dextromethorphan	(10	μmol/L)	for	oocytes	transfected	with	either	GluN2AWT 
or	GluN2AN615K	–containing	NMDA	receptors,	voltage‐clamped	at	–60	mV.	An	independent	Welch	t‐test	showed	that	GluN2AN615K was 
associated	with	an	increase	in	block	(WT:	45	±	2	(n	=	7	oocytes),	N615K:	55	±	3	(n	=	8	oocytes),	t12.6	=	2.8,	P	=	0.015)
2A WT 2A N615K(A) (B) (C)
(D) (E) (F)
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conductance	value	obtained	here	using	technically	“gold	standard”	
outside‐out patches is in good agreement with that obtained using 
cell–attached	patches	containing	GluN2AN615K diheteromeric re‐
ceptors	expressed	in	human	embryonic	kidney	(HEK293T)	cells.12 
The reduction in cation conductance seen likely reflects the in‐
troduction of a positively charged residue at a constriction of the 
pore.10 This region has already been shown to determine conduct‐
ance	by	mutation	studies	in	GluN1	and	GluN2B	subunits.19‐21 The 
reduction	 in	conductance	 is	 likely	to	disrupt	the	receptor's	 iono‐
tropic signaling function and thus potentially impair both neuro‐
transmission	and	plasticity.	However,	a	reduction	in	conductance	
is	unlikely	to	be	amenable	to	therapeutic	modification	by	existing	
small molecules.
In	conclusion,	this	study	found	that	the	human	disease–associ‐
ated	variant	GluN2AN615K has marked effects on inhibition by chan‐
nel blockers and single–channel conductance. The channel blocker 
dextromethorphan	is	a	potential	candidate	for	possible	therapeutic	
use.
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